UTHR director exercises options and sells 2,910 shares
UNITED THERAPEUTICS Corp director Christopher Patusky exercised and sold company stock under a pre-set plan.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
UNITED THERAPEUTICS Corp director Christopher Patusky exercised and sold company stock under a pre-set plan. He exercised stock options for 2,910 shares of common stock at $101.80 per share and, on the same day, sold 2,910 shares at $569.00 per share in an open-market transaction.
The filing states these transactions were carried out under a Rule 10b5-1 trading plan entered into on December 18, 2025. After the sale, he held 1,490 shares directly and 1,100 shares indirectly through a trust, and the exercised stock option covering 2,910 shares was fully used.
Insider Trade Summary 10b5-1
Exercise and Sale: 2,910 shares ($1.36M approx. pre-tax spread)
Exercise and Sale
4 txns
Insider
PATUSKY CHRISTOPHER
Role
Director
Sold
2,910 shs ($1.66M)
Approx. gross sale proceeds
$1.66M
Approx. exercise cost
$296K
Approx. pre-tax spread
$1.36M
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Stock Option | 2,910 | $0.00 | $0.00 |
| Exercise | Common Stock | 2,910 | $101.80 | $296K |
| Sale | Common Stock | 2,910 | $569.00 | $1.66M |
| holding | Common Stock | -- | -- | -- |
Holdings After Transaction:
Stock Option — 0 contracts (Direct);
Common Stock — 1,490 shares (Direct);
Common Stock — 1,100 shares (Indirect, by Trust)
Footnotes (1)
- F1. This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on December 18, 2025.
Key Figures
Shares sold: 2,910 shares
Sale price: $569.00 per share
Shares exercised: 2,910 shares
+5 more
8 metrics
Shares sold
2,910 shares
Open-market sale of common stock on April 24, 2026
Sale price
$569.00 per share
Price for 2,910 common shares sold
Shares exercised
2,910 shares
Common stock acquired via stock option exercise
Exercise price
$101.80 per share
Conversion or exercise price of stock option
Direct holdings after
1,490 shares
Common stock held directly following transactions
Indirect holdings after
1,100 shares
Common stock held indirectly by trust
Option exercisable since
June 21, 2017
Stock option exercise date reference
Option expiration
June 21, 2026
Expiration date of exercised stock option
Key Terms
Rule 10b5-1 trading plan, stock options, open-market sale, derivative security, +1 more
5 terms
Rule 10b5-1 trading plan regulatory
"This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan"
A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.
stock options financial
"This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan"
Stock options are agreements that give a person the right to buy or sell a company's stock at a specific price within a certain time frame. They are often used as a reward or incentive, similar to a coupon that can be used later if the stock price rises, allowing the holder to make a profit.
open-market sale financial
"transaction_action": "open-market sale""
An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.
derivative security financial
"transaction_code_description": "Exercise or conversion of derivative security""
A derivative security is a financial contract whose value comes from the price or performance of something else, such as a stock, bond, commodity, or market index. For investors it acts like an insurance policy or a wager: it can be used to protect against losses, lock in prices, or amplify gains and losses, so it can change a portfolio’s risk and potential return without owning the underlying asset directly.
indirect ownership financial
"ownership_type": "indirect""
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transactions did UNITED THERAPEUTICS (UTHR) director Christopher Patusky report?
Christopher Patusky reported exercising stock options for 2,910 UNITED THERAPEUTICS (UTHR) shares at $101.80 and selling 2,910 common shares at $569.00. The exercise and sale occurred on the same day as part of an options exercise-and-sell pattern.
Was the UNITED THERAPEUTICS (UTHR) insider sale made under a Rule 10b5-1 plan?
Yes. The filing states the option exercise and subsequent sale by UNITED THERAPEUTICS (UTHR) director Christopher Patusky were executed pursuant to a Rule 10b5-1 trading plan entered into on December 18, 2025, indicating the transactions were pre-arranged rather than opportunistic.
What stock options did the UNITED THERAPEUTICS (UTHR) director exercise?
He exercised a stock option for 2,910 UNITED THERAPEUTICS (UTHR) shares with a conversion or exercise price of $101.80 per share. The option, originally exercisable from June 21, 2017, had an expiration date of June 21, 2026, and was fully exercised in this transaction.
Does the director still hold any UNITED THERAPEUTICS (UTHR) stock options after this Form 4?
The filing shows a stock option for 2,910 UNITED THERAPEUTICS (UTHR) shares going from 2,910 to zero following exercise, and the derivative summary is empty. This indicates that particular option grant was fully exercised with no remaining balance reported.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Accepted by SEC EDGAR
Learn about SEC filing dates